

Innovation from a Patient-First Perspective

Agenda

*Subject to Change

Wednesday, June 4, 2025 – Day 1

10:00

DCAT Welcome

DCAT President, Donna Gruol
DCAT Executive Director, Carol Lee

10:10 - 10:30

Regional Welcome

Mayor of Lugano, Michele Foletti Director of Economy Division of the Canton of Ticino, Stefano Rizzi

Master of Ceremonies

Winpak Heat Seal, Inc. Tara Wojcik, Business Integration Manager

10:30 - 11:30

Session I: Redefining Value – Supply Chain Integrity, Patient-Centric Development & Health Equity

This session explores how a more inclusive, transparent, and patient-focused approach to pharmaceutical development and supply chain management can drive meaningful changes across the industry. From safeguarding material authenticity to reimagining development pathways through the lens of gender and patient experience, presenters will share strategies that prioritize quality, access, and equity.

Kearney, Paula Bellostas Muguerza, Partner Rx360, Jim Fries, Chief Executive Officer Arcondis, Atanas Todorov, Chief Medical Officer

Presenters will discuss how **collaboration, transparency, and inclusivity** can lead to higher-quality care, more effective therapies, and stronger patient outcomes while also driving operational excellence and societal impact.



Innovation from a Patient-First Perspective

11:30 - 11:45 MORNING NETWORKING REFRESHMENTS

11:45 - 12:15 Session I: Moderated Panel Discussion

MODERATOR

Kearney, Suraj Mathew, Partner

PANELISTS

Kearney, Paula Bellostas Muguerza, Partner Rx360, Jim Fries, Chief Executive Officer Arcondis, Atanas Todorov, Chief Medical Officer

12:15 - 13:15 LUNCHEON

13:15 - 15:00 Session II: Innovation at the Foundation –
Development, Manufacturing & Supply

This session begins at the earliest stages of the pharmaceutical supply chain—development and manufacturing—highlighting how companies are transforming operations to meet the demands of an increasingly complex global marketplace.

FUJIFILM Diosynth Biotechnologies, Jordan Ulrich, VP Project Delivery/Capital Projects and Jacobs Engineering, Dana Tilley, Sr. VP & GM Life Sciences North America Flamma SpA, Georgio Bertollini, Group General Manager Johnson Matthey, Antonio Zanotti Gerosa, R&D Director Life Science Technology PCI Pharma, Justin Schroeder, VP Global Technical Services

These presentations demonstrate how **technological innovation**, **sustainability**, **and datacentric strategies** reshape the industry's speed, scalability, and supply reliability approach.



Innovation from a Patient-First Perspective

15:00 - 15:40 Session II: Moderated Panel Discussion

MODERATOR

Bio X Cell, Chris Conway, Chief Executive Officer & DCAT Director

PANELISTS

FUFIFILM Diosynth Biotechnologies, Jordan Ulrich, VP Project Delivery/Capital Projects Flamma SpA, Georgio Bertollini, Group General Manager Johnson Matthey, Antonio Zanotti Gerosa, R&D Director Life Science Technology Just Evotec, Christophe Martin, Sr. Director, Business Development Europe PCI Pharma, Justin Schroeder, VP Global Technical Services

15:40 - 16:10

AFTERNOON NETWORKING REFRESHMENTS

16:00 - 16:45

Keynote: Recorded Fireside Chat with Dr. Yusuf Hamied,
Chairman (retired) of Cipla Ltd. and Dr. Paolo Magri,
Bioseutica and former DCAT President

A special pre-recorded conversation gives attendees rare insights into the legacy, leadership, and lasting impact of one of the pharmaceutical industry's most transformative figures. Dr. Hamied has been internationally recognized for his unwavering commitment to making medicines affordable and accessible, especially in the battle against HIV/AIDS and other global health crises.

With a deep-rooted belief in patient-first innovation, Dr. Hamied's leadership continues to influence how the industry balances scientific progress with a humanitarian purpose. His reflections and perspectives should not be overlooked.



Innovation from a Patient-First Perspective

16:45 - 17:00

Keynote Q&A: Kamil Hamied, Former Chief Strategy Officer and current Non-Executive Promoter Director of Cipla, and Dr. Paolo Magri

Mr. Kamil Hamied is an alumnus of United World College and New York University.

Kamil is a seasoned entrepreneur with extensive experience in the pharmaceutical industry and wider healthcare sectors. He has successfully navigated business across Asia, Europe, and the US. During his entrepreneurial journey, Kamil also ventured into the investment realm, establishing an investment platform focused on the broader life sciences, biotechnology, genomics, Al drug development, diagnostics, etc.

In his previous stint at Cipla, Kamil was the Chief Strategy Officer and a member of the management team. He was involved in leading company transformation, M&A strategy, implementing a leadership structure and more.

17:00 - 17:10 Closing Remarks

Winpak Ltd, Tara Wojcik, Business Integration Manager, Global Pharma Accounts

17:30 - 19:30

Networking Cocktail Reception & Entertainment

LOCATION

Villa Ciani Palazzo dei Congressi



Innovation from a Patient-First Perspective

Thursday, June 5, 2025 - Day 2

8:00 - 8:50 Good Morning Breakfast

8:50 - 9:00 Opening Address

West Pharmaceutical Services, Stacey Vaughan, Vice President Marketing and Portfolio Management

Master of Ceremonies

West Pharmaceutical Services, Inc., Stacey Vaughan, VP Marketing & Portfolio Management

9:00 - 10:20 Session III: Advanced Therapies & Biologics -

Accelerating Development with Next-Generation Manufacturing

This session highlights how leading companies are advancing the development and production of biologics and advanced therapies by leveraging integrated platforms, digital infrastructure, and flexible manufacturing models. The presentations spotlight technologies that reduce development timelines, improve scalability, and enable precision-targeted treatments in oncology and beyond.

Made Scientific, David Smith, VP and Head of Development Eli Lilly & Company, Jesus Castanon, Sr. Director, Discovery Chemistry Axplora, Arul Ramadurai, Chief Commercial Officer enGene, Anthony T. Cheung, Ph.D., Chief Scientific Officer

Presenters will explore how **manufacturing innovation**, **digital connectivity**, **and patient-focused design** are converging to transform the advanced therapies landscape—accelerating time to market while maintaining safety, consistency, and clinical impact.



Innovation from a Patient-First Perspective

10:20 - 10:50 Session III: Moderated Panel Discussion

MODERATOR

Made Scientific, Syed Husain, Chief Executive Officer

PANELISTS

Made Scientific, David Smith, VP and Head of Development Eli Lilly & Company, Jesus Castanon, Sr. Director, Discovery Chemistry Axplora, Arul Ramadurai, Chief Commercial Officer enGene, Anthony T. Cheung, Ph.D., Chief Scientific Officer

10:50 - 11:20 MORNING NETWORKING REFRESHMENTS

11:20 - 11:55 Keynote 2: Dr. Mohamed Aburawi, Innovating for Impact

Dr. Mohamed Aburawi, a Libya-born surgeon and tech entrepreneur, is the founder and CEO of Atarona Ventures, where he leads the creation and scaling of transformational, high-impact ventures across global health, education, financial inclusion, and energy access. Passionate about bold ideas that accelerate social progress, Mohamed's work is dedicated to minimizing suffering and fostering inclusive prosperity for the next billion people in some of the world's most impoverished regions.

Focusing on his native Libya, Dr. Aburawi explores how technology can dismantle barriers to quality care and promote health care as a fundamental human right. Aburawi is a visionary entrepreneur committed to transforming healthcare accessibility and education in regions facing conflict and economic challenges.

Through initiatives like Speetar, he aims to establish resilient care systems that provide immediate medical services and empower communities for sustainable development. His focus on supporting vulnerable groups like women and children in crisis situations underscores his commitment to equitable healthcare and education opportunities.

By leveraging innovative technology and forging global partnerships, Mohamed strives to ensure that every individual has the chance to thrive, irrespective of their circumstances. His work embodies a mission to ensure universal access to healthcare. and education a reality worldwide.



Innovation from a Patient-First Perspective

MODERATOR

Arcondis, Marie Skinner, Head of Sales

12:15 - 13:15 **LUNCHEON**

13:15 - 14:15 Session IV: Transforming Drug Formulation:

Enhancing Solubility, Patient Compliance and

Manufacturing Sustainability

This session explores groundbreaking advances in drug formulation that improve the solubility of poorly soluble drugs, streamline dosage forms, and enhance patient compliance—particularly for populations with swallowing difficulties or multiple comorbidities. With nearly 70% of drugs in development exhibiting low solubility, the need for novel delivery approaches has never been greater.

Nanoform, Christian Jones, Chief Commercial Officer NanoPharma Solutions, Kay Olmstead, Chief Executive Officer dsm-firmenich, Athanasia Kanli, Sr. Director Global Marketing & Business Development Manager

Presenters will address the technological, regulatory, and patient-centric drivers behind these innovations and share insights into the financial outcomes, scalability, and lifecycle management of new and mature products.

14:15 - 14:45 Session IV: Moderated Panel Discussion

MODERATOR

dsm-firmenich, Kelsey Achenbach, VP Pharmaceutical Business & DCAT First Vice President

PANELISTS

Nanoform, Christian Jones, Chief Commercial Officer NanoPharma Solutions, Kay Olmstead, Chief Executive Officer dsm-firmenich, Athanasia Kanli, Sr. Director, Marketing & Business Development Manager



Innovation from a Patient-First Perspective

14:45 - 15:15 AFTERNOON NETWORKING REFRESHMENTS

15:15 - 16:00 Capstone Panel: Creating Patient Value in a Misaligned World

In today's rapidly shifting global landscape, stakeholder expectations, regulatory frameworks, geopolitical forces and healthcare access are becoming increasingly disconnected. How can the industry realign its efforts to create meaningful, sustainable value for patients? The Summit's capstone panel tackles this urgent question head-on, bringing together a powerhouse group of 4-5 thought leaders for a dynamic, cross-cutting discussion that ties together the most critical themes explored throughout the program. Topics on the table include drug pricing and affordability, the evolving regulatory environment (including the EU Medicines Act and U.S. PILL Act), the impact of tariffs on branded and generic therapies, global access challenges, supply chain vulnerabilities, and the transformative influence of Al.

This can't-miss session goes beyond identifying problems. It will challenge assumptions, spotlight tensions between commercial imperatives and patient outcomes, and uncover opportunities for innovation. Join the conversation and leave inspired, informed, and better equipped to drive real patient-centered change in an increasingly complex business ecosystem.

MODERATOR

Eli Lilly and Company, Michael Semo, Associate Vice President, External Sourcing & DCAT Third Vice President

PANELISTS

Icrom, Pierfrancesco Morosini, Chief Executive Officer & DCAT Director Nanoform, Christian Jones, Chief Commercial Officer PCI Pharma, Justin Schroeder, VP Global Technical Services Rx360, Jim Fries, Chief Executive Officer

16:00 - 16:40 Closing Keynote: Mr. Benjamin Hall, Veteran War Correspondent

A veteran war correspondent, Mr Hall was critically injured while reporting on the front lines in Ukraine when a multi-sequential rocket attack struck him and his team. Tragically, two members of his crew – cameraman Pierre Zakrewski and journalist Oleksandra "Sasha" Kuvshinova- lost their lives. Mr. Hall's survival was uncertain, and his journey forward became a testament to resilience, global collaboration, and the unwavering power of innovation in patient care.

Mr. Halls's story exemplifies the very essence of a patient-first mindset. His recovery was made possible by the extraordinary efforts of medical teams, technological advances and the human spirit. He will share his inspiring account of survival and the role that courage, science and compassionate care played in his path to healing.

His powerful message reminds us why innovation, inspiration and transformation are critical to the future of the global bio/pharmaceutical industry – and why the work we do matters.



Innovation from a Patient-First Perspective

16:40 - 17:00 Closing Keynote Q&A

MODERATOR

Lone Fox Endeavors, Donna Gruol, President and Founder & DCAT President

17:00 - 17:15 Closing Remarks & Thank you

Donna Gruol, DCAT President & Summit at Lugano Task Force Chairperson

19:30 - 22:30 Networking Cocktail & Dinner Reception

LOCATION

Hotel Splendide Royal Lugano Riva Antonio Caccia 7 6900 Lugano, Switzerland